Abbott Laboratories $ABT Shares Sold by Strs Ohio

Strs Ohio lowered its holdings in Abbott Laboratories (NYSE:ABT) by 6.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 566,197 shares of the healthcare product maker’s stock after selling 35,951 shares during the quarter. Strs Ohio’s holdings in Abbott Laboratories were worth $75,836,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. State Street Corp grew its position in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after acquiring an additional 689,517 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after buying an additional 1,390,554 shares during the last quarter. Norges Bank purchased a new position in shares of Abbott Laboratories during the second quarter worth about $3,026,180,000. Finally, Massachusetts Financial Services Co. MA increased its position in Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $108.50 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23. The stock has a market capitalization of $188.67 billion, a P/E ratio of 13.60, a PEG ratio of 2.00 and a beta of 0.72. The business’s fifty day moving average price is $125.23 and its 200 day moving average price is $128.54.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 31.58%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech / devices strength helped offset weakness elsewhere — management said Devices/MedTech delivered solid growth in Q4, cushioning the hit from Nutrition and Diagnostics. Read More.
• Positive Sentiment: Adjusted EPS and margins improved — adjusted EPS grew ~12% and matched street expectations, with margin gains driven by product mix and cost improvements. This supports the company’s cash generation and capital-return capacity. Read More.
• Neutral Sentiment: Reported EPS met consensus ($1.50), limiting the severity of the selloff from an earnings-surprise perspective. Read More.
• Negative Sentiment: Revenue missed expectations — Q4 revenue was below consensus ($~11.5B vs. ~$11.8B est), driven by a contraction in Nutrition (~‑9%) and weakness in Diagnostics (lower COVID testing and aid-related volatility). That top‑line miss is the main catalyst for the decline. Read More.
• Negative Sentiment: Guidance came in slightly below street models — Q1 EPS guide (1.120–1.180) and FY 2026 adjusted EPS (5.550–5.800) skated under consensus, which amplified selling pressure given the revenue shortfall. Read More.
• Negative Sentiment: Unusual bearish options activity — traders bought a large volume of puts (reported ~80,600), signaling elevated short‑term hedging or directional bearish bets that can accelerate downward moves in the stock.
• Negative Sentiment: Market reaction and media coverage — widespread headlines on the revenue miss and weaker outlook pushed the shares lower and into fresh downside territory, with analysts noting the pullback even as most maintain constructive long‑term views. Read More.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ABT. Sanford C. Bernstein lifted their target price on Abbott Laboratories from $150.00 to $154.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating on the stock in a research note on Friday, January 9th. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Evercore ISI upped their price target on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Finally, Benchmark started coverage on Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $147.39.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.